A systematic review of the evidence of clozapine's anti-aggressive effects

International Journal of Neuropsychopharmacology

Volumn 15, Issue 9, 2012, Pages 1351-1371

  Frogley, Catherine ^a   Taylor, David ^a,b   Dickens, Geoff ^a   Picchioni, Marco ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aggression; clozapine; schizophrenia; violence

Indexed keywords

BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RIMCAZOLE; RISPERIDONE; SPIPERONE; SULPIRIDE; TRIFLUOPERAZINE;

AGGRESSION; AKATHISIA; AUTISM; BIPOLAR DISORDER; BORDERLINE STATE; COGNITION; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DSM-III-R; DSM-IV; HOSTILITY; HUMAN; ICD-10; IMPULSIVENESS; LATENT PERIOD; LEARNING DISORDER; LOW DRUG DOSE; MENTAL HEALTH CARE; MORTALITY; NEGATIVE SYNDROME; NONHUMAN; OBSERVATIONAL STUDY; OUTPATIENT CARE; POSITIVE SYNDROME; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SOCIAL ISOLATION; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIOLENCE;

ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; VIOLENCE;

EID: 84871489770     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571100201X     Document Type: Review

References (151)

1. Agid O, Arenovich T, Sajeev G, Zipursky RB, et al. (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72, 1439-1444.
2. APA (2004). American Psychiatric Association : practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161, 1-56.
3. Arango C, Bombin I, Gonzalez-Salvador T, Garcia-Cabeza I, et al. (2006). Randomised clinical trial comparing oral vs. depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry 21, 34-40.
4. Ascher-Svanum H, Faries D, Zhu B, Ernst FR, et al. (2006). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67, 453-460.
5. Asenjo CA, Komossa K, Leucht S, Hunger H, et al. (2010). Clozapine vs. other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. Issue No. 11. Article No.: CD006633.
6. Averbeck BB, Evans S, Chouhan V, Bristow E, et al. (2011). Probabilistic learning and inference in schizophrenia. Schizophrenia Research 127, 115-122.
7. Balbuena L, Mela M, Wong S, Gu D, et al. (2010). Does clozapine promote employability and reduce offending among mentally disordered offenders? Canadian Journal of Psychiatry 55, 50-56.
8. Barrett EA (2011). Neurocognitive functioning and suicidality in schizophrenia spectrum disorders. Comprehensive Psychiatry 52, 156-163.
9. Becker A, Grecksch G (2003). Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus. Pharmacology Biochemistry and Behavior 76, 1-8.
10. Beer DM, Khan A, Ratnajothy K (2007). The effect of clozapine on adverse incidents in a low-secure challenging behaviour unit. Journal of Psychiatric Intensive Care 2, 65-70.
11. Beherec L, Lambrey S, Quilici G, Rosier A, et al. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology 31, 341-344.
12. Benedetti F, Sforzini L, Colombo C, Maffei C, et al. (1998). Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Journal of Clinical Psychiatry 59, 103-107.
13. Bilder RM, Goldman RS, Volavka J, Czobor P, et al. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 159, 1018-1028.
14. Bitter I, Czobor P, Dossenbach M, Volavka J (2005). Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile behaviour in outpatients treated for schizophrenia : a prospective naturalistic study (IC SOHO). European Psychiatry 20, 403-408.
15. Boachie A, McGinnity MGA (1997). Use of clozapine in a mental handicap hospital-report of the first 17 patients. Irish Journal of Psychological Medicine 14, 16-19.
16. Breier A, Buchanan W, Kirkpatrick B, Davis OR, et al. (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 151, 20-26.
17. Brunette M, Dawson R, O'Keefe CD, Noordsy DL, et al. (2011). Clozapine vs. other antipsychotics for schizophrenia and co-occuring cannabis use disorder. Schizophrenia Bulletin 37 (Suppl. 1), 297.
18. Buckley P, Bartell J, Donenwirth K, Lee S, et al. (1995). Violence and schizophrenia : clozapine as a specific antiaggressive agent. Bulletin of the American Academy of Psychiatry and the Law 23, 607-612.
19. Buckley PF, Shendarkar N (2005). Treatment-refractory schizophrenia. Current Opinion in Psychiatry 18, 165-173.
20. Chakos M, Lieberman J, Hoffman E, Bradford D, et al. (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia : a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518-526.
21. Chalasani L, Kant R, Chengappa KNR (2001). Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Canadian Journal of Psychiatry 46, 965-968.
22. Chau DT, Gulick D, Xie H, Dawson R, et al. (2010). Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology 58, 351-356.
23. Chengappa KNR, Ebeling T, Kang JS, Levine J, et al. (1999). Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry 60, 477-484.
24. Chengappa KNR, Vasile J, Levine J, Ulrich R, et al. (2002). Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia Research 53, 1-6.
25. Chiles JA, Davidson P, McBride D (1994). Effects of clozapine on use of seclusion and restraint at a state hospital. Hospital and Community Psychiatry 45, 269-271.
26. Chow EWC, Bury AS, Roy R, Basset AS, et al. (1996). The effect of clozapine on aggression. A randomised controlled study. Abstracts of the 149th Annual Meeting of the American Psychiatric Association, 4-9 May, 170.
27. Citrome L, Volavka J (2000). Management of violence in schizophrenia. Psychiatric Annals 30, 41-52.
28. Citrome L, Volavka J, Czobor P, Sheitman B, et al. (2001). Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 52, 1510-1514.
29. Cohen SA, Underwood MT (1994). The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry 55, 440-444.
30. Dalal B, Larkin E, Leese M, Taylor PJ (1999). Clozapine treatment of long-standing schizophrenia and serious violence : a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Criminal Behaviour and Mental Health 9, 168-178.
31. De Domenico P, Di Rosa AE, D'Agostino AA, Martino G, et al. (1999). The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia. International Journal of Psychiatry in Clinical Practice 3, 49-54.
32. De Hert M, Correll CU, Cohen D (2010). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research 117, 68-74.
33. de Leon J, Diaz FJ, Josiassen RC, Cooper TB, et al. (2005). Does clozapine decrease smoking? Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 757-762.
34. Dixon AK, Huber C, Lowe DA (1994). Clozapine promotes approach-oriented behavior in male mice. Journal of Clinical Psychiatry 55 (9 Suppl. B), 4-7.
35. Douglas KS, Guy LS, Hart SD (2009). Psychosis as a risk factor for violence to others : a meta-analysis. Psychological Bulletin 135, 679-706.
36. Dursun SM, Szemis A, Andrews H, Whitaker P, et al. (2000). Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia : a cross-sectional study. Journal of Psychiatry and Neuroscience 25, 347-352.
37. Dyer KFW, Dorahy MJ, Hamilton G, Corry M, et al. (2009). Anger, aggression, and self-harm in PTSD and complex PTSD. Journal of Clinical Psychology 65, 1099-1114.
38. Ebrahim GM, Gibler B, Gacono CB, Hayes G, et al. (1994). Patient response to clozapine in a forensic psychiatric hospital. Hospital and Community Psychiatry 45, 271-273.
39. Essali A, Al-Haj Hassan N, Rathbone J (2009). Clozapine vs. typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews. Issue No. 1. Art. No. CD000059.
40. Fazel S, Gulati G, Linsell L, Geddes JR, et al. (2009). Schizophrenia and violence : systematic review and metaanalysis. PLoS Medicine 6, 1-15.
41. Fazel S, Langstrom N, Hjern A, Grann M, et al. (2009). Schizophrenia, substance abuse, and violent crime. Journal of the American Medical Association 301, 2016-2023.
42. Frankenburg FR, Zanarini MC (1993). Clozapine treatment of borderline patients : a preliminary study. Comprehensive Psychiatry 34, 402-405.
43. Frankle WG, Shera D, Berger-Hershkowitz H, Evins AE, et al. (2001). Clozapine-associated reduction arrest rates, of psychotic patients with criminal histories. American Journal of Psychiatry 158, 270-274.
44. Gallitano-Mendel A, Wozniak DF, Pehek EA, Milbrandt J (2008). Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects. Neuropsychopharmacology 33, 1266-1275.
45. Garmendia L, Sanchez JR, Azpiroz A, Brain PF, et al. (1992). Clozapine: strong antiaggressive effects with minimal motor impairment. Physiology and Behavior 51, 51-54.
46. Gelly F, Chambon O, Marie-Cardine M (1997). Long-term clinical experience with clozapine. Experience clinique de longue duree de la clozapine 23, 385-396.
47. Girgis RR, Phillips MR, Xiaodong L, Kejing L, et al. (2011). Clozapine v. chlorpromazine in treatment-naive, firstepisode schizophrenia : 9-year outcomes of a randomised clinical trial. British Journal of Psychiatry 199, 281-288.
48. Glazer WM, Dickson RA (1998). Clozapine reduces violence and persistent aggression in schizophrenia. Journal of Clinical Psychiatry 59 (Suppl. 3), 8-14.
49. Gobbi G, Pulvirenti L (2001). Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. Journal of Psychiatry and Neuroscience 26, 340-341.
50. Grace J, Bellus SP, Raulin ML, Herz ML, et al. (1996). Longterm impact of clozapine and psychosocial treatment of psychiatric symptoms and cognitive functioning. Psychiatric Services 4, 41-45.
51. Green A, Burgess ES, Dawson R, Zimmet SV, et al. (2003). Alcohol and cannabis use in schizophrenia : effects of clozapine vs. risperidone. Schizophrenia Research 60, 81-85.
52. Green A, Chau DT, Gulick D, Ahmed J, et al. (2011). Deconstructing clozapine: toward medication development for alcoholism in schizophrenia. Schizophrenia Bulletin 37 (Suppl. 1), 288.
53. Green A, Noordsy DL, Brunette M, O'Keefe CD (2008). Substance abuse and schizophrenia : pharmacotherapeutic intervention. Journal of Substance Abuse Treatment 34, 61-71.
54. Hagger C, Buckley P, Kenny JT, Freidman L, et al. (1993). Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34, 702-712.
55. Hammock R, Levine WR, Schroeder SR (2001). Brief report : effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation. Journal of Autism and Developmental Disorders 31, 109-113.
56. Hennen J, Baldessarini RJ (2005). Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 73, 139-145.
57. Herrera JN, Sramek JJ, Costa JF, Roy S, et al. (1988). High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 176, 558-561.
58. Hillbrand M (1995). Aggression against self and aggression against others in violent psychiatric patients. Journal of Consulting and Clinical Psychology 63, 668-671.
59. Hodgins S, Cree A, Alderton J, Mak T (2008). From conduct disorder to severe mental illness : associations with aggressive behaviour, crime and victimization. Psychological Medicine 38, 975-987.
60. Huband N, Ferriter M, Nathan R, Jones H (2010). Antiepileptics for aggression and associated impulsivity. Cochrane database of Systematic Reviews. Issue No. 2. Art No. CD003499.
61. Iancu I, Bodner E, Roitman S, Piccone SA, et al. (2010). Impulsivity, aggression and suicide risk among male schizophrenia patients. Psychopathology 43, 223-229.
62. Ilgen MA, Burnette ML, Conner KR, Czyz E, et al. (2010). The association between violence and lifetime suicidal thoughts and behaviours in individuals treated for substance use disorders. Addictive Behaviours 35, 111-115.
63. Joyal CC, Gendron C, Cote G (2008). Nature and frequency of aggressive behaviours among long-term inpatients with schizophrenia: a 6-month report using the modified overt aggression scale. Canadian Journal of Psychiatry 53, 478-481.
64. Kane J, Honigfeld G, Singer J, Meltzer HY, et al. (1988). Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry 45, 789-796.
65. Kane J, Schooler N, Marder SR, Wirshing W, et al. (1996). Efficacy of clozapine vs. haloperidol in a long-term clinical trial. Schizophrenia Research 18, 127.
66. Kay SR, Wolkenfelf F, Murrill LM (1988). Profiles of aggression among psychiatric patients : I. nature and prevalence. Journal of Nervous and Mental Disease 176, 539-546.
67. Kim E, Gupta S, Bolge S, Chen CC, et al. (2010). Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. Journal of Medical Economics 13, 185-192.
68. Koike H, Ibi D, Mizoguchi H, Nagai T, et al. (2009). Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behavioural Brain Research 202, 114-121.
69. Kowatch RA, Suppes T, Gilfillan SK, Fuentes RM, et al. (1995). Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia : a clinical case series. Journal of Child and Adolescent Psychopharmacology 5, 241-253.
70. Krakowski M, Czobor P (2011). Neurocognitive impairment limits the response to treatment of aggression with antipsychotic agents. Schizophrenia Bulletin 37 (Suppl. 1), 311-312.
71. Krakowski MI, Czobor P, Citrome L, Bark N, et al. (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622-629.
72. Krakowski MI, Czobor P, Nolan KA (2008). Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Journal of Clinical Psychopharmacology 28, 485-493.
73. Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, et al. (2005). Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 44, 55-63.
74. Kraus JE, Sheitman B (2005). Clozapine reduces violent behavior in heterogeneous diagnostic groups. Journal of Neuropsychiatry and Clinical Neurosciences 17, 36-44.
75. Krü ger C, Rosema D (2010). Risk factors for violence among long-term psychiatric in-patients : a comparison between violent and non-violent patients. African Journal of Psychiatry 13, 366-375.
76. Kumari V, Barkataki I, Goswami S, Flora S, et al. (2009). Dysfunctional, but not functional, impulsivity is associated with a history of seriously violent behaviour and reduced orbitofrontal and hippocampal volumes in schizophrenia. Psychiatry Research Neuroimaging 173, 39-44.
77. Lambrey S, Falissard B, Martin-Barrero M, Bonnefoy C, et al. (2010). Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. Journal of Child and Adolescent Psychopharamacology 20, 79-80.
78. Lee MA, Jayathilake K, Meltzer H (1999). A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophrenia Research 37, 1-11.
79. Leucht S, Corves C, Arbter D, Engel RR, et al. (2009). Second-generation vs. first-generation antipsychotic drugs for schizophrenia : a meta-analysis. Lancet 373, 31-41.
80. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 14, 429-447.
81. Lincoln TM, Lange J, Burau J, Exner C, et al. (2010). The effect of state anxiety on paranoid ideation and jumping to conclusions. An experimental investigation. Schizophrenia Bulletin 36, 1140-1148.
82. Lindstrom LH (1994). Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatrica Scandinavica (Suppl.) 380, 74-76.
83. Link BG, Stueve A, Phelan J (1998). Psychotic symptoms and violent behaviors: probing the components of 'threat/control-override' symptoms. Social Psychiatry and Psychiatric Epidemiology 33, S55-S60.
84. Maier GJ (1992). The impact of clozapine on 25 forensic patients. Bulletin of the American Academy of Psychiatry and the Law 20, 297-307.
85. Mallyer AR, Roos PD, Roebuck-Colgan K (1992). Restraint, seclusion and clozapine. Journal of Clinical Psychiatry 53, 395-397.
86. Mangalore R, Knapp M (2007). Cost of schizophrenia in England. Journal of Mental Health Policy and Economics 10, 23-41.
87. Manu P, Sarpal D, Muir O, Kane JM, et al. (2011). When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophrenia Research 134, 180-186.
88. McEvoy J, Freudenreich O, WilsonWH (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry 46, 125-129.
89. McMillen BA, DaVanzo EA, Song AH, Scott SM, et al. (1989). Effects of classical and atypical antipsychotic drugs on isolation-induced aggression in male mice. European Journal of Pharmacology 160, 149-153.
90. Meltzer H, McGurk SR (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255.
91. Meltzer HY, Alphs L, Green AI, Altamura C, et al. (2003). Clozapine treatment for suicidality in schizophrenia. Archives of General Psychiatry 60, 82-91.
92. Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 41, 892-897.
93. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia : impact on risk-benefit assessment. American Journal of Psychiatry 152, 183-190.
94. Menditto AA, Beck NC, Stuve P, Fisher JA, et al. (1996). Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Psychiatric Services 47, 46-51.
95. Michals ML, Crimson ML, Roberts S, Childs A (1993). Clozapine response and adverse effects in nine brain injured patients. Journal of Clinical Psychopharmacology 13, 198-203.
96. Milovanovic D, Maric J, et al. (1974). Clozapine in the treatment of schizophrenic psychoses [in Serbocroatian]. An. Zavod. Ment. Zdrav. 6, 41-49.
97. Modai I, Hirschmann S, Rava A, Kurs R, et al. (2000). Sudden death in patients receiving clozapine treatment: a preliminary investigation. Journal of Clinical Psychopharmacology 20, 325-327.
98. Modestin J, Dal Pian D, Agarwalla P (2005). Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Journal of Clinical Psychiatry 66, 534-538.
99. Munro J, O'Sullivan D, Andrews C, Arana A, et al. (1999). Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. British Journal of Psychiatry 175, 576-580.
100. NICE (2010). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). NICE clinical guideline 82. Department of Health, London, UK.
101. Niskanen P, Achte K, Jaskari M (1974). Results of a comparative double blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatrica Fennica 307-313.
102. Nolan K, Czobor P, Roy BB, Platt MM, et al. (2003). Characteristics of assaultive behavior among psychiatric inpatients. Psychiatric Services 54, 1012-1016.
103. Nolan KA, D'Angelo D, Hoptman MJ (2011). Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls. Psychiatry Research 187, 301-303.
104. Parker GF (2002). Clozapine and borderline personality disorder. Psychiatric Services 53, 348-349.
105. Phelan J, Link BG (1998). The growing belief that people with mental illness are violent : the role of the dangerousness criterion for civil commitment. Social Psychiatry and Psychiatric Epidemiology 33, 7-12.
106. Popova NK (2008). From gene to aggressive behavior: the role of brain serotonin. Neuroscience and Behavioural Psychology 38, 471-475.
107. Popova NK, Naumenko VS, Kozhemyakina RV, Plyusnina IZ (2010). Functional characteristics of serotonin 5-HT2A and 5-HT2C receptors in the brain and the expression of the 5-HT2A and 5-HT2C receptor genes in aggressive and non-aggressive rats. Neuroscience and Behavioural Psychology 40, 357-361.
108. Potkin SG, Alphs L, Hsu C, Krishnan KRT, et al. (2003). Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biological Psychiatry 54, 444-452.
109. Rabinowitz J, Avnon M, Rosenberg V (1996). Effect of clozapine on physical and verbal aggression. Schizophrenia Research 22, 249-255.
110. Ratey JJ, Leveroni C, Kilmer D, Gutheil C, et al. (1993). The effects of clozapine on severely aggressive psychiatric inpatients in a State Hospital. Journal of Clinical Psychiatry 54, 219-223.
111. Ravanic DB, Djukic Dejanovic SM, Janjic V, Jovic SD, et al. (2009). Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period. Arquivos de Neuro-Psiquiatria 67, 195-202.
112. Reid WH, Mason M, Hogan T (1998). Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services 49, 1029-1033.
113. Reid WH, Mason M, Toprac M (1994). Savings in hospital bed-days related to treatment with clozapine. Hospital and Community Psychiatry 45, 261-264.
114. Rewerski W, Kostowski W, Piechocki T (1979). Effects of some neuroleptic drugs on aggressive behaviour in isolated mice. Acta Physiologica Polonica 30, 295-298.
115. Rimon R, Kuoppasalmi K, Naukkarinen H, Lang S, et al. (1994). Clozapine decreases the level of anxiety and aggressive behaviour in patients with therapy-refractory schizophrenia. Nordic Journal of Psychiatry 48, 315-320.
116. Rosenheck R, Chang S, Choe Y, Cramer J, et al. (2000). Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 61, 382-386.
117. Sernyak MJ, Desai R, Stolar M, Rosenheck R (2001). Impact of clozapine on completed suicide. American Journal of Psychiatry 158, 931-937.
118. Sharif ZA, Raza A, Ratakonda SS (2000). Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder : a retrospective analysis. Journal of Clinical Psychiatry 61, 498-504.
119. Shrivastava A, Shah N, Johnson M, Stitt L, et al. (2010). Predictors of long-term outcome of first-episode schizophrenia: a ten-year follow-up study. Indian Journal of Psychiatry 52, 320-326.
120. Singer K, Lam CM (1973). Evaluation of leponex (Clozapine) in schizophrenia with acute symptomatology. Journal of International Medical Research 1, 627-629.
121. Smith H, White T (2004). The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital. Medicine, Science and the Law 44, 213-216.
122. Smith J, Hucker S (1994). Schizophrenia and substance abuse. British Journal of Psychiatry 165, 13-21.
123. Spivak B, Mester R, Wittenberg N, Maman Z, et al. (1997). Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clinical Neuropharmacology 20, 442-446.
124. Spivak B, Roitman S, Vered Y, Mester R, et al. (1998). Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on Clozapine. Clinical Neuropharmacology 21, 245-250.
125. Spivak B, Shabash E, Sheitman B, Weizman A, et al. (2003). The effects of clozapine vs. haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients : an open, nonrandomized, 6-month study. Journal of Clinical Psychiatry 64, 755-760.
126. Steinert T, Wiebe C, Gebhardt RT (1999). Aggressive behaviours against self and others among first-admission patients with schizophrenia. Psychiatric Services 50, 85-90.
127. Stoner SC, Wehner Lea JS, Dubisar BM, Roebuck-Colgan K, et al. (2002). Impact of clozapine vs. haloperidol on conditional release time and rates of revocation in a forensic psychiatric population. Journal of Pharmacy Technology 18, 182-186.
128. Strous RD, Kupchik M, Roitman S, Schwartz S, et al. (2006). Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia : a naturalistic prospective 12-week observational study. Human Psychopharmacology 21, 235-243.
129. Swanson JW, Dom Van RA, Swartz MS, Smith A, et al. (2008a). Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behaviour problems. Law and Human Behaviour 32, 228-240.
130. Swanson JW, Swartz M, Van Dorn RA, Elbogen EB, et al. (2006). A National Study of Violent Behaviour in Persons with Schizophrenia. Archives of General Psychiatry 63, 490-499.
131. Swanson JW, Swartz MS, Elbogen EB (2004). Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin 30, 3-20.
132. Swanson JW, Swartz MS, Van Dorn RA, Volavka J, et al. (2008b). Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry 193, 37-43.
133. Swartz MS, Swanson JW, Hiday V, Borum R, et al. (1998). Violence and severe mental illness : the effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 155.
134. Swinton M (2001). Clozapine in severe borderline personality disorder. Journal of Forensic Psychiatry 12, 580-591.
135. Swinton M, Haddock A (2000). Clozapine in Special Hospital: a retrospective case-control study. Journal of Forensic Psychiatry 11, 587-596.
136. Tiihonen T, Lonnqvist J, Wahlbeck K, Klaukka T, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia : a population-based cohort study (FIN11 study). Lancet 374, 620-627.
137. Topiwala A, Fazel S (2011). The pharmacological management of violence in schizophrenia : a structured review. Expert Review of Neurotherapeutics 11, 53-63.
138. Van Dorn RA, Andel R, Boaz TL, Desmarais SL, et al. (2011). Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioural health services. Journal of Clinical Psychiatry 72, 502-508.
139. Volavka J (1999). The effects of clozapine on aggression and substance abuse in schizophrenic patients. Journal of Clinical Psychiatry 60, 43-46.
140. Volavka J, Citrome L (2008). Heterogeneity of violence in schizophrenia and implications for long-term treatment. International Journal of Clinical Practice 62, 1237-1245.
141. Volavka J, Czobor P, Nolan K, Sheitman B, et al. (2004). Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology 24, 225-228.
142. Volavka J, Swanson JW (2010). Violent behaviour in mental illness : the role of substance abuse. Journal of the American Medical Association 304, 3-4.
143. Volavka J, Zito JM, Vitrai J, Czobor P (1993). Clozapine effects on hostility and aggression in schizophrenia. Journal of Clinical Psychopharmacology 13, 287-289.
144. Walker AM, Lee Lanza L, Arellano F, Rothman K (1997). Mortality in current and former users of clozapine. Epidemiology 8, 671-677.
145. Walsh E, Buchanan A, Fahy T (2002). Violence and Schizophrenia : examining the evidence. British Journal of Psychiatry 180, 490-495.
146. Wheatley M, Plant J, Reader H, Brown G, et al. (2004). Clozapine treatment of adolescents with posttraumatic stress disorder and psychotic symptoms. Journal of Clinical Psychopharmacology 24, 167-173.
147. Wilson WH (1992). Clinical review of clozapine treatment in a state hospital. Hospital and Community Psychiatry 43, 700-703.
148. Wilson WH, Claussen AM (1995). 18-Month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. Psychiatric Services 46, 386-389.
149. Yudofsky SC, Silver JM, Jackson W, Endicott J, et al. (1986). The overt aggression scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry 143, 35-39.
150. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, et al. (2000). Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder : a retrospective survey. Journal of Clinical Psychopharmacology 20, 94-98.
151. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C (1996). Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry 153, 737-738.